76.84
price up icon0.58%   0.44
pre-market  Pre-mercato:  77.03   0.19   +0.25%
loading
Precedente Chiudi:
$76.40
Aprire:
$76.94
Volume 24 ore:
20.64M
Relative Volume:
1.32
Capitalizzazione di mercato:
$192.95B
Reddito:
$63.92B
Utile/perdita netta:
$17.43B
Rapporto P/E:
11.18
EPS:
6.87
Flusso di cassa netto:
$17.04B
1 W Prestazione:
-0.95%
1M Prestazione:
-9.29%
6M Prestazione:
-24.40%
1 anno Prestazione:
-38.30%
Intervallo 1D:
Value
$75.59
$77.56
Intervallo di 1 settimana:
Value
$75.59
$78.20
Portata 52W:
Value
$73.31
$134.63

Merck Co Inc Stock (MRK) Company Profile

Name
Nome
Merck Co Inc
Name
Telefono
908-740-4000
Name
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
Dipendente
75,000
Name
Cinguettio
@Merck
Name
Prossima data di guadagno
2025-02-04
Name
Ultimi documenti SEC
Name
MRK's Discussions on Twitter

Confronta MRK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
MRK
Merck Co Inc
76.84 194.81B 63.92B 17.43B 17.04B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
737.67 640.72B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.21 367.98B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
186.11 323.71B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.76 222.69B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.50 299.26B 43.59B 15.04B 10.74B 3.3766

Merck Co Inc Stock (MRK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-14 Downgrade Citigroup Buy → Neutral
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-02-18 Downgrade Deutsche Bank Buy → Hold
2025-02-10 Downgrade TD Cowen Buy → Hold
2025-01-08 Downgrade Truist Buy → Hold
2024-12-20 Downgrade BMO Capital Markets Outperform → Market Perform
2024-12-10 Ripresa BofA Securities Buy
2024-12-04 Aggiornamento HSBC Securities Hold → Buy
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-11 Downgrade Daiwa Securities Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-03-11 Downgrade Societe Generale Hold → Sell
2024-01-04 Aggiornamento TD Cowen Market Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Buy
2023-10-27 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-10-20 Aggiornamento UBS Neutral → Buy
2023-07-14 Iniziato HSBC Securities Hold
2023-04-13 Aggiornamento Citigroup Neutral → Buy
2023-03-28 Downgrade Societe Generale Buy → Hold
2023-03-13 Downgrade Wells Fargo Overweight → Equal Weight
2023-03-06 Iniziato Jefferies Buy
2023-02-22 Aggiornamento Wolfe Research Peer Perform → Outperform
2023-01-04 Aggiornamento BofA Securities Neutral → Buy
2022-11-18 Iniziato Credit Suisse Outperform
2022-10-10 Aggiornamento Guggenheim Neutral → Buy
2022-09-14 Aggiornamento Berenberg Hold → Buy
2022-07-06 Aggiornamento Daiwa Securities Neutral → Buy
2022-06-06 Ripresa SVB Leerink Outperform
2022-04-06 Ripresa Morgan Stanley Equal-Weight
2021-12-17 Iniziato Goldman Buy
2021-12-16 Iniziato Daiwa Securities Neutral
2021-12-13 Downgrade UBS Buy → Neutral
2021-12-09 Iniziato Wells Fargo Overweight
2021-12-07 Downgrade Guggenheim Buy → Neutral
2021-11-29 Downgrade Citigroup Buy → Neutral
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-01 Aggiornamento Argus Hold → Buy
2021-09-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-07-27 Ripresa Truist Buy
2021-05-20 Downgrade Argus Buy → Hold
2021-04-07 Ripresa RBC Capital Mkts Sector Perform
2020-11-10 Ripresa Bernstein Outperform
2020-09-29 Iniziato Berenberg Hold
2020-08-03 Aggiornamento Goldman Neutral → Buy
2020-06-12 Downgrade Wolfe Research Outperform → Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-01-07 Iniziato RBC Capital Mkts Sector Perform
2019-10-17 Ripresa BofA/Merrill Neutral
2019-08-16 Iniziato SVB Leerink Outperform
2019-07-03 Iniziato Mizuho Buy
2019-05-28 Iniziato Goldman Neutral
2019-05-13 Aggiornamento Atlantic Equities Neutral → Overweight
2018-10-16 Reiterato Citigroup Buy
2018-10-09 Ripresa Guggenheim Buy
2018-04-23 Aggiornamento Goldman Neutral → Buy
2018-04-17 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-04-05 Aggiornamento Barclays Equal Weight → Overweight
2018-03-12 Aggiornamento Leerink Partners Mkt Perform → Outperform
2018-02-14 Reiterato Leerink Partners Mkt Perform
2018-02-07 Reiterato Morgan Stanley Equal-Weight
2018-01-16 Aggiornamento SunTrust Hold → Buy
Mostra tutto

Merck Co Inc Borsa (MRK) Ultime notizie

pulisher
12:06 PM

FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More - BioSpace

12:06 PM
pulisher
Jun 01, 2025

Merck's (MRK) Keytruda-Trodelvy Combo Shows Significant Benefits in Breast Cancer Treatment | MRK Stock News - GuruFocus

Jun 01, 2025
pulisher
May 31, 2025

Gilead Sciences, Inc, (GILD)’s Trodelvy and Merck & Co., Inc, (MRK)’s Keytruda Cuts Breast Cancer Progression Risk by 35% - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Merck & Co., Inc. (MRK)’s MK-1084 Shows Promise in Early Cancer Trial - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Merck & Co., Inc. (MRK) Reports Positive Trial Results for DLBCL Drug - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Merck Says Keytruda® Plus Trodelvy® Reduced Risk Of Disease Progression Or Death By 35% Versus Keytruda Plus Chemotherapy In First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer - marketscreener.com

May 31, 2025
pulisher
May 30, 2025

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small - insights.citeline.com

May 30, 2025
pulisher
May 30, 2025

Jim Cramer on Merck & Co (MRK): ‘I’ve Got To Take a Hard Look At It’ - MSN

May 30, 2025
pulisher
May 30, 2025

Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers - Benzinga

May 30, 2025
pulisher
May 30, 2025

Merck (MRK) Sees Promising Results in Cancer Drug Trial - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Merck releases positive early-stage data on colorectal cancer and NSCLC asset - Seeking Alpha

May 30, 2025
pulisher
May 30, 2025

Merck (MRK) Antibody Drug Shows Promise in Lymphoma Trial - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Merck antibody drug conjugate asset shows antitumor activity in phase 2 - Seeking Alpha

May 30, 2025
pulisher
May 30, 2025

Merck CEO Calls Diversity ‘Core’ to Operations as Anti-DEI Measure Is Defeated - BioSpace

May 30, 2025
pulisher
May 30, 2025

Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - MSN

May 30, 2025
pulisher
May 30, 2025

Merck Reports Antitumor Activity With Experimental KRAS Inhibitor MK-1084 in Early Trial - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Merck Says Potential Lymphoma Therapy Achieves 56.3% Response Rate in Phase 2 Study - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Merck (MRK) Reports Promising Phase 2/3 Trial Results for Cancer Therapy | MRK Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Merck reports promising results for cancer drug MK-1084 By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Merck reports promising DLBCL treatment results By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Merck reports promising results for cancer drug MK-1084 - Investing.com

May 30, 2025
pulisher
May 30, 2025

Here’s Why Merck & Co. (MRK) Traded Lower in Q1 - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

Merck reports promising DLBCL treatment results - Investing.com

May 30, 2025
pulisher
May 30, 2025

Merck'S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial - Business Wire

May 30, 2025
pulisher
May 30, 2025

Merck’s West Point Presence Remains Strong Amid Riverside Closure - BUCKSCO.Today

May 30, 2025
pulisher
May 29, 2025

Transcript : Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Bernstein 41st Annual Strategic Decisions Conference - Merck.com

May 29, 2025
pulisher
May 29, 2025

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS - insights.citeline.com

May 29, 2025
pulisher
May 29, 2025

Merck & Co To Present At Bernstein Strategic Decisions Conference; Webcast At 3:30 PM ET - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer - Reuters

May 29, 2025
pulisher
May 29, 2025

Merck & Co. Concludes Annual Shareholders Meeting - TipRanks

May 29, 2025
pulisher
May 29, 2025

Merck shareholders approve board, executive pay at annual meeting By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Merck shareholders approve board, executive pay at annual meeting - Investing.com

May 29, 2025
pulisher
May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

Merck, Daiichi pull approval application for ADC in lung cancer - BioPharma Dive

May 29, 2025
pulisher
May 29, 2025

Merck: voluntary withdrawal of a BLA in lung cancer - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Is Merck Stock Underperforming the Nasdaq? - MSN

May 29, 2025
pulisher
May 29, 2025

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Merck (MRK) and Daiichi Sankyo Withdraw U.S. Application for Lung Cancer Therapy - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Is Merck Stock Underperforming The Nasdaq? - Barchart.com

May 29, 2025
pulisher
May 29, 2025

Merck (MRK) Withdraws Biologics License Application for Patritum - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Merck stock drops as BLA for lung cancer drug is pulled (MRK) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Merck Withdraws Biologics License Application for Patritumab Deruxtecan - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Major Setback: Merck's Advanced Lung Cancer Drug Falls Short in Crucial Survival Trial - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Abbisko Secures $85 Million from Merck for Pimicotinib Global Rights - TipRanks

May 29, 2025
pulisher
May 28, 2025

Dow falls nearly 250 points on losses in Merck, Nike shares - MSN

May 28, 2025
pulisher
May 28, 2025

Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight - PR Newswire UK

May 28, 2025

Merck Co Inc Azioni (MRK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general GSK
$41.03
price up icon 2.58%
$288.18
price up icon 1.64%
drug_manufacturers_general NVO
$71.50
price up icon 2.94%
drug_manufacturers_general NVS
$115.76
price up icon 2.82%
$110.08
price down icon 0.93%
Capitalizzazione:     |  Volume (24 ore):